NCT00366522已完成1 期
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家开始时间: 2006年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
- 主要终点
- Safety and Tolerability
研究概览
简要总结
To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, men or women, aged 19-50 years
- •Use of any investigational or prescription drug within 30 days before study start
- •Any clinically imprtant medical disease or abnormal laboratory test results
排除标准
- 未提供
结局指标
主要结局
Safety and Tolerability
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Evaluating LXR-623 in Healthy Japanese AdultsHealthyNCT00385489Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
A Safety Study of LY3462817 in Healthy ParticipantsHealthyNCT03715192Eli Lilly and Company64
终止
1 期
Study Evaluating HTC-867 in Healthy Young and Elderly SubjectsHealthy SubjectsNCT00827489Wyeth is now a wholly owned subsidiary of Pfizer72
撤回
1 期
Study Evaluating Single Doses of GAP-134Healthy SubjectsNCT00820521Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy SubjectsHealthyNCT00550381Wyeth is now a wholly owned subsidiary of Pfizer72